Patents Assigned to KuDos Pharmaceuticals Limited
-
Publication number: 20070049588Abstract: A compound of formula (I): and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, and their use in treating diseases ameliorated by the inhibition of ATM.Type: ApplicationFiled: August 30, 2006Publication date: March 1, 2007Applicant: KuDOS Pharmaceuticals LimitedInventors: Graeme Smith, Niall Martin, Andrew Slade, Keith Menear, Marc Hummersone, Xiao-Ling Cockcroft, Ian Matthews, Laurent Rigoreau, Roger Griffin, David Newell, Nicola Curtin
-
Patent number: 7151102Abstract: A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula: or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein: A and B together represent an optionally substituted, fused aromatic ring; RC is represented by —L—RL, where L is of formula: —(CH2)n1-Qn2-(CH2)n3— wherein n1, n2 and n3 are each selected from 0, 1, 2 and 3, the sum of n1, n2 and n3 is 1, 2 or 3 and Q is selected from O, S, NH, C(?O) or —CR1R2—, where R1 and R2 are independently selected from hydrogen, halogen or optionally substituted C1-7 alkyl, or may together with the carbon atom to which they are attached form a C3-7 cyclic alkyl group, which may be saturated (a C3-7 cycloalkyl group) or unsaturated (a C3-7 cycloalkenyl group), or one of R1 and R2 may be attached to an atom in RL to form an unsaturated C3-7 cycloalkenyl group which comprises the carbon atoms to which R1 and R2 are aType: GrantFiled: October 30, 2001Date of Patent: December 19, 2006Assignees: Kudos Pharmaceuticals Limited, Maybridge PLCInventors: Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Charles Richard White, Roger Frank Newton, Diane Gillian Douglas, Penny Jane Eversley, Julia Vile
-
Publication number: 20060264623Abstract: Compounds of formula l: wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N;and (iii) CH, O, C; are disclosed for use in inhibiting DNA-PK.Type: ApplicationFiled: April 13, 2006Publication date: November 23, 2006Applicants: KuDOS Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Xiao-ling Cockcroft, Mark Frigerio, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, Hilary Calvert, Nicola Curtin, Marine Desage-El Murr
-
Publication number: 20060264427Abstract: Compounds of formula I: wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N;and (iii) CH, O, C; the dotted lines represent two double bonds in the appropriate locations; and where Z is selected from S, O, C(?O), CH2 and NH are disclosed for use in inhibiting DNA-PK.Type: ApplicationFiled: April 13, 2006Publication date: November 23, 2006Applicants: KuDOS Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Xiao-ling Cockcroft, Mark Frigerio, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, HiIary Calvert, Nicola Curtin, Kappusamy Saravanan, Marine Desage-El Murr
-
Patent number: 7138236Abstract: The interaction of ATM and related protein kinases such as ATR and DNA-PK with p53 is disclosed, in particular the phosphorylation of Ser15 and Thr18 by these proteins. The activity of the proteins is shown to increase in the presence of DNA. Assays for modulators of phosphorylation by the interaction between the proteins and p53 or other proteins having similar phosphorylation sites are provided. Methods of purifying ATM or ATR employing DNA or NTA are also disclosed.Type: GrantFiled: July 16, 1998Date of Patent: November 21, 2006Assignee: Kudos Pharmaceuticals LimitedInventors: Stephen Philip Jackson, Nicholas David Lakin, Graeme Cameron Murray Smith
-
Publication number: 20060178361Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 together form, along with the nitrogen atom to which they are attached, an optionally substituted nitrogen containing heterocyclic ring having from 4 to 8 ring atoms; and R3 is selected from hydroxy and —NRN1RN2, where RN1 and RN2 are independently selected from hydrogen, optionally substituted C1-7 alkyl groups, optionally substituted C3-20 heterocyclyl groups and optionally substituted C5-20 aryl groups, or together form, along with the nitrogen atom to which they are attached, an optionally substituted nitrogen containing heterocyclic ring having from 4 to 8 ring atoms, and its use in inhibiting ATM.Type: ApplicationFiled: February 9, 2006Publication date: August 10, 2006Applicant: Kudos Pharmaceuticals LimitedInventors: Marc Hummersone, Keith Menear, Laurent Rigoreau, Graeme Smith, Niall Martin, Roger Griffin
-
Publication number: 20060149059Abstract: Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.Type: ApplicationFiled: December 23, 2005Publication date: July 6, 2006Applicants: Kudos Pharmaceuticals Limited, Maybridge LimitedInventors: Niall Martin, Graeme Smith, Stephen Jackson, Vincent Loh, Xiao-Ling Cockcroft, Ian Matthews, Keith Menear, Frank Kerrigan, Alan Ashworth
-
Publication number: 20060142293Abstract: A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula: or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein: A and B together represent an optionally substituted, fused aromatic ring; RC is represented by -L-RL, where L is of formula: —(CH2)n1-Qn2-(CH2)n3— wherein n1, n2 and n3 are each selected from 0, 1, 2 and 3, the sum of n1, n2 and n3 is 1, 2 or 3 and Q is selected from O, S, NH, C(?O) or —CR1R2—, where R1 and R2 are independently selected from hydrogen, halogen or optionally substituted C1-7 alkyl, or may together with the carbon atom to which they are attached form a C3-7 cyclic alkyl group, which may be saturated (a C3-7 cycloalkyl group) or unsaturated (a C3-7 cycloalkenyl group), or one of R1 and R2 may be attached to an atom in RL to form an unsaturated C3-7 cycloalkenyl group which comprises the carbon atoms to which R1 and R2 are aType: ApplicationFiled: February 10, 2006Publication date: June 29, 2006Applicants: Kudos Pharmaceuticals Limited, Maybridge plcInventors: Niall Martin, Graeme Smith, Charles White, Roger Newton, Diane Douglas, Penny Eversley, Julia Vile
-
Publication number: 20060106025Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(?O)— or —O—; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3, or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(?O)—NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl gType: ApplicationFiled: September 20, 2005Publication date: May 18, 2006Applicants: Kudos Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Laurent Rigoreau, Roger Griffin, Bernard Golding, David Newell, Hilary Calvert, Nicola Curtin, Ian Hardcastle, Kappusamy Saravanan
-
Publication number: 20050059663Abstract: Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X?NRX then n is 1 or 2 and if X?CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.Type: ApplicationFiled: June 24, 2004Publication date: March 17, 2005Applicants: Kudos Pharmaceuticals Limited, Maybridge LimitedInventors: Niall Morrison Martin, Graeme Smith, Stephen Jackson, Vincent M Loh, Xiao-Ling Cockcroft, Ian Timothy Matthews, Keith Menear, Frank Kerrigan, Alan Ashworth
-
Publication number: 20050054657Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and RN1 is selected from hydrogen, an optionally substituted C1-7 alkyl group, an optionally substituted C3-20 heterocyclyl group, an optionally substituted C5-20 aryl group, an acyl group, an ester group and an amido group, and its use as a pharmaceutical.Type: ApplicationFiled: August 13, 2004Publication date: March 10, 2005Applicant: KuDOS Pharmaceuticals LimitedInventors: Graeme Smith, Niall Martin, Xiao-Ling Cockcroft, Ian Matthews, Keith Menear, Laurent Rigoreau, Marc Hummersone, Roger Griffin
-
Patent number: 6753158Abstract: A yeast homologue of mammalian DNA ligase IV is provided and a role for DNA ligase IV established in the Ku-associated DNA repair pathway. Additionally interactions between DNA ligase IV and XRCC4, and interaction between XRCC4 and DNA-PKcs/Ku are established, providing for assays for agents which modulate such interactions and therefore cellular DNA repair activity. Such agents are useful in treatment of cancers, retroviral infections, immune system disorders and other conditions in which cellular DNA repair activity plays a role. Individuals with a predisposition to a disorder in which DNA repair plays a role may be diagnosed, by screening for the presence or absence of a defect in XRCC4 and/or DNA ligase IV activity.Type: GrantFiled: July 12, 1999Date of Patent: June 22, 2004Assignee: Kudos Pharmaceuticals LimitedInventors: Stephen Philip Jackson, Susan Elizabeth Critchlow
-
Patent number: 6753151Abstract: Ku is a protein found in a wide range of organisms. It comprises two tightly-associated subunits termed Ku70 and Ku80. The present invention relates to the discovery and characterisation of an interaction between Ku70 and Ku80 and DNA-PKCS. Various applications based on this interaction are provided. These are relevant to numerous cellular processes which are of interest in therapeutic contexts.Type: GrantFiled: May 11, 2000Date of Patent: June 22, 2004Assignee: Kudos Pharmaceuticals LimitedInventors: Stephen P. Jackson, David A. Gell
-
Publication number: 20040023968Abstract: A compound of formula: 1Type: ApplicationFiled: April 29, 2003Publication date: February 5, 2004Applicants: KuDOS Pharmaceuticals Limited, Maybridge plcInventors: Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Penny Jane Eversley, Xiao-Ling Cockcroft, Frank Kerrigan, Janet Hoare, Lesley Dixon
-
Patent number: 6664269Abstract: Derivatives of isoquinolinone and dihydrolisoquinolinone, and related compounds, and their use as pharmaceuticals in the treatment of a disease by inhibition of the enzyme poly(ADP-ribose)polymerase (“PARP”) are disclosed.Type: GrantFiled: April 30, 2002Date of Patent: December 16, 2003Assignees: Maybridge plc, KuDOS Pharmaceuticals LimitedInventors: Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Charles Richard White, Roger Frank Newton, Diana Gillian Douglas, Penny Jane Eversley, Alan John Whittle
-
Publication number: 20030008896Abstract: Derivatives of isoquinolinone and dihydrolisoquinolinone, and related compounds, and their use as pharmaceuticals in the treatment of a disease by inhibition of the enzyme poly(ADP-ribose)polymerase (“PARP”) are disclosed.Type: ApplicationFiled: April 30, 2002Publication date: January 9, 2003Applicant: KuDOS Pharmaceuticals LimitedInventors: Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Charles Richard White, Roger Frank Newton, Diana Gillian Douglas, Penny Jane Eversley, Alan John Whittle
-
Publication number: 20020183325Abstract: A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula: 1Type: ApplicationFiled: October 30, 2001Publication date: December 5, 2002Applicant: KuDOS Pharmaceuticals LimitedInventors: Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Charles Richard White, Roger Frank Newton, Diane Gillian Douglas, Penny Jane Eversley, Julia Vile
-
Patent number: 6242175Abstract: Ku(Ku70 and Ku80) of yeast and mammalian cells and other components of the Ku-associated DNA repair pathway are involved in retrotransposon and retroviral integration into cellular nucleic acids. Agents which inhibit activity of the pathway are useful for inhibition of retroviruses. Such agents are obtainable using assays involving the Ku-associated DNA repair pathway and one or more components thereof.Type: GrantFiled: July 12, 1999Date of Patent: June 5, 2001Assignee: KuDos Pharmaceuticals LimitedInventors: Stephen Philip Jackson, Jessica Anne Downs